Brief summary of scenario *
|
I recently chaired a regional rheumatology medicines governance group, where the processes and pathways for prescribing a new biological treatment were discussed and agreed. This required the committee to agree on how (and by who) the medicine would be prescribed, who would be responsible for the monitoring of the medicine, and the communication and documentation requirements needed.
During the meeting there were strongly-held, opposing views from different stakeholders, including GPs, pharmacists, hospital consultant medics, and service managers. I needed to manage the discussion to a point where a consensus could be found.
|